AstralBio

MA - BostonBiotechnology1 H-1B visas (FY2023)

Focus: AstralBio is a private biotechnology company specializing in machine learning-driven antibody discovery for oncology applications. Stage and scale are opaque due to missing funding and headcount data.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About AstralBio

AI assessmentNot Hiring

No open roles listed right now. Follow AstralBio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

AMPICILLIN AND SULBACTAM

bacterial infections (susceptible strains)

Post-LOE

Legacy generic antibiotics post-loss of exclusivity; unlikely to be core to AstralBio's future oncology-focused pipeline.

Help build intelligence for AstralBio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

AI/ML-first drug discovery platform in high-value oncology space offers exposure to cutting-edge computational biology methods
Boston headquarters provides access to major biotech ecosystem and research institutions
Private stage allows potential for equity upside if company advances pipeline and achieves funding milestones

Watch Out For

Zero active job openings signals company may not be in active hiring phase or is pre-revenue with limited hiring capacity
No disclosed pipeline programs or clinical trials visible, indicating early discovery stage with uncertain clinical de-risking timeline
Missing critical data on funding, headcount, and financial trajectory makes stability assessment impossible

Generated by Claude from AstralBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CEFTRIAXONE

bacterial infections (pneumonia, S. aureus, H. influenzae)

Post-LOE

Post-LOE generic cephalosporin; inconsistent with stated specialty in ML antibody discovery for oncology.

CEFEPIME HYDROCHLORIDE

bacterial pneumonia (moderate to severe)

Post-LOE

Post-LOE generic; portfolio indicates legacy generics portfolio unrelated to core ML platform focus.

PIPERACILLIN AND TAZOBACTAM

appendicitis, peritonitis (beta-lactamase producing E. coli)

Post-LOE

Post-LOE antibiotic combination; appears to be legacy asset unrelated to machine learning oncology platform strategy.